Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million
Company Details
- Employees
- 33
- Founded
- -
- Address
- Av. Ernest Lluch 32, Tcm2, Mataró,barcelona 08302,spain
- Phone
- 34 93 702 19 75
- in****@****ryx.com
- Industry
- Biotechnology
- Website
- minoryx.com
- Keywords
- Rare diseases, Neurometabolic diseases, X-linked Adrenoleukodystrophy, Friedreich's Ataxia, Orphan CNS.
- HQ
- Mataró, Barcelona
Minoryx Therapeutics Questions
Minoryx Therapeutics's helpline number is 34 93 702 19 75
Minoryx Therapeutics's website is minoryx.com
Minoryx Therapeutics's LinkedIn profile is https://es.linkedin.com/company/minoryx-therapeutics
Minoryx Therapeutics has
33 employees.
View email and phone details for 33
employees at Minoryx Therapeutics.
Minoryx Therapeutics's industry is
Biotechnology
Minoryx Therapeutics's top competitors are
Highlight Therapeutics Sl,
Mimark Diagnostics,
Oryzon Genomics Sa,
Oxolife,
Peptomyc,
Aelix Therapeutics,
Catalonia.health,
Ona Therapeutics,
Splicebio,
Nuage Therapeutics.
Minoryx Therapeutics's support email address is info@minoryx.com
Minoryx Therapeutics's categories are Biotechnology
Minoryx Therapeutics's founding year is 2011
